Denali Therapeutics Inc. (FRA:4DN)

Germany flag Germany · Delayed Price · Currency is EUR
17.00
+0.41 (2.47%)
At close: Nov 28, 2025
-27.04%
Market Cap2.46B
Revenue (ttm)n/a
Net Income (ttm)-425.08M
Shares Outn/a
EPS (ttm)-2.48
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume975
Average Volume187
Open16.65
Previous Close16.59
Day's Range16.65 - 17.00
52-Week Range10.17 - 24.28
Betan/a
RSI68.62
Earnings DateFeb 27, 2026

About Denali Therapeutics

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; DNL343 eIF2B activator program for amyotrophic lateral sclerosis; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme r... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2013
Employees 422
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 4DN
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.